US PRE-MARKET MOVERS: AZN, COST, PEP, LEVI, CBRS, IBM, MSFT, ENVX, AZZ, FCEL, CRM, PSKY
US pre-market is volatile as AstraZeneca's trial failure and PepsiCo's inflation warnings offset gains in AI infrastructure (CBRS) and leadership hires (ENVX). Starbucks' shift to internal AI tools pressures software vendors.
News detail
ES +0.2% NQ +0.9% RTY +0.3% AZN -8.0%: Wainua failed to meet its target in Phase III trial COST -1.7%: Total SSS growth in June eased from May PEP -2.7%: Earnings weighed by consumer budgets tightening; expects high input cost inflation in H2 vs H1 LEVI -4.0%: Q3 & FY26 outlook disappointed CBRS +5.3%: Announced a major expansion of its European AI infrastructure IBM -4.3%, MSFT -1.8%: SBUX is reportedly developing in-house tools with the help of AI that could replace some software applications it now buys from companies such as MSFT & IBM ENVX +12.2%: Appointed former Director of Product Operations at Apple, Michael Vyvoda, as COO AZZ +7.5%: EPS & rev. beat FCEL +10.7%: Announced a collaboration with Siemens to accelerate the deployment of fuel cell-based distributed power generation. CRM -4.7%: Downgraded at KeyBanc to 'Sector Weight' from 'Overweight' PSKY -2.6%: Downgraded at Arete to 'Sell' from 'Neutral'
Related stocks
12 stocksWhat do investors think?
StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.
